Molecular Partners AG, a pioneer in the development of a novel class of therapeutic proteins termed DARPins, has announced the appointment of Jörn Aldag as Chairman of the Board of Directors.
Jörn Aldag is President and CEO of Evotec. After the successful IPO in 1999, he was instrumental in growing Evotec from a small technology provider to one of the leading drug discovery and development companies with a promising CNS pipeline in Europe.
Dr. Christian Zahnd, CEO of Molecular Partners welcomed Jörn Aldag to the board: “Jörn brings the experience, strategic vision and dedication to help advance Molecular Partners and build on the full potential of the Company’s DARPin technology. His experience in developing pharmaceutical businesses will be key as we further grow Molecular Partners.”
Commenting on his appointment, Jörn Aldag added: “Molecular Partners’ novel class of therapeutic compounds shows great potential in providing new therapies for unmet clinical needs. This is an exciting time for Molecular Partners and I am delighted to have this opportunity to contribute to the expansion of the Company and to become part of this dedicated team.”
Prior to Evotec, Jörn Aldag was Vice President and Finance Director of MAN Gutehoffnungshütte AG, a subsidiary of MAN AG, Munich and Business Director of Treuhandanstalt, the privatization agency for East German businesses after the reunification. Jörn Aldag is currently a Member of the Monopoly Commission of the Federal Republic of Germany. Jörn Aldag holds business degrees from the Harvard Business School and the European Business School.